Arcturus Therapeutics Holdings

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARCT and other ETFs, options, and stocks.

About ARCT

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. 

CEO
Joseph E. Payne
CEOJoseph E. Payne
Employees
111
Employees111
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2013
Founded2013
Employees
111
Employees111

ARCT Key Statistics

Market cap
234.49M
Market cap234.49M
Price-Earnings ratio
-2.93
Price-Earnings ratio-2.93
Dividend yield
Dividend yield
Average volume
455.39K
Average volume455.39K
High today
$8.41
High today$8.41
Low today
$8.15
Low today$8.15
Open price
$8.41
Open price$8.41
Volume
81.69K
Volume81.69K
52 Week high
$24.17
52 Week high$24.17
52 Week low
$5.85
52 Week low$5.85

Stock Snapshot

The current Arcturus Therapeutics Holdings(ARCT) stock price is $8.25, with a market capitalization of 234.49M. The stock trades at a price-to-earnings (P/E) ratio of -2.93.

During the trading session on 2026-05-13, Arcturus Therapeutics Holdings(ARCT) shares reached a daily high of $8.41 and a low of $8.15. At a current price of $8.25, the stock is +1.2% higher than the low and still -1.9% under the high.

Trading volume for Arcturus Therapeutics Holdings(ARCT) stock has reached 81.69K, versus its average volume of 455.39K.

Over the past 52 weeks, Arcturus Therapeutics Holdings(ARCT) stock has traded between a high of $24.17 and a low of $5.85.

Over the past 52 weeks, Arcturus Therapeutics Holdings(ARCT) stock has traded between a high of $24.17 and a low of $5.85.

ARCT News

TipRanks 5d
Arcturus Therapeutics Signals Progress Amid Revenue Slip

Arcturus Therapeutics ((ARCT)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data a...

The Motley Fool 5d
Arcturus Q1 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, May 7, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Joseph Payne Chief Medical Offic...

Arcturus Q1 2026 Earnings Call Transcript
TipRanks 6d
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

75%

of 12 ratings
Buy
75%
Hold
25%
Sell
0%

More ARCT News

TipRanks 6d
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)

Reports Q1 revenue $2.1M, consensus $6.9M. “Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated enrollment of our 12-week C...

People also own

Based on the portfolios of people who own ARCT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.